Haleon (HLN) investor relations material

Financial guidance and performance

• Guidance remains second-half weighted, with a minimum expected growth of 3.5%, potentially higher if the cold/flu season is strong.

• U.S. market faces muted growth and inventory pressures, but other regions (EMEA, LATAM, Asia-Pacific) are expected to accelerate.

• Volume mix is closely tracked, with a balanced approach between volume and price contributing to organic growth.

• Inventory destocking in the U.S. is expected to persist, with proactive management to avoid out-of-stocks.

• Oral health continues to outperform, while smoker’s health remains a drag but is expected to stabilize with new innovation.

Channel and geographic strategy

• Strong partnerships with major retailers like Walmart and Amazon, with higher brand shares online than in brick-and-mortar.

• Channel shift from drug stores to mass retailers is ongoing, with a focus on winning in both traditional and emerging channels.

• U.S. market share is growing overall, with particular strength in oral health and plans to stabilize brands like Advil.

• BMS (vitamins/supplements) faces challenges in the U.S. but is growing in emerging markets, supported by science-backed claims.

Innovation and portfolio development

• Sensodyne’s clinical platform is expanding globally, with new products like Clinical Enamel and low-income consumer packs.

• Paradontax is now in about 60 countries, with resource allocation enabling mid-teens growth, especially in China.

• China JV buyout unlocks operational synergies, cost savings, and broader pharmacy reach, improving financial returns.

• India is a key growth market, with distribution expansion and tailored products for low-income consumers supporting acceleration.